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Abstract Changes in synapse structure occur in frontal
neocortex with HIVencephalitis (HIVE) and may contribute
to HIV-associated neurocognitive disorders (HAND). A
postmortem survey was conducted to determine if mRNAs
involved in synaptic transmission are perturbed in dorsolat-
eral prefrontal cortex (DLPFC) in subjects with HIVE or
HAND. Expression of the opioid neurotransmitter preproen-
kephalin mRNA (PENK) was significantly decreased in a
sampling of 446 brain specimens from HIV-1 infected peo-
ple compared to 67 HIV negative subjects. Decreased
DLPFC PENK was most evident in subjects with HIVE
and/or increased expression of interferon regulatory factor
1 mRNA (IRF1). Type 2 dopamine receptor mRNA
(DRD2L) was decreased significantly, but not in the same
set of subjects with PENK dysregulation. DRD2L down-
regulation occurred primarily in the subjects without HIVE
or neurocognitive impairment. Subjects with neurocognitive
impairment often failed to significantly downregulate
DRD2L and had abnormally high IRF1 expression. Conclu-
sion: Dysregulation of synaptic preproenkephalin and
DRD2L in frontal neocortex can occur with and without
neurocognitive impairment in HIV-infected people. Down-
regulation of DRD2L in the prefrontal cortex was associated
with more favorable neuropsychological and neuropatho-
logical outcomes; the failure to downregulate DRD2L was
significantly less favorable. PENK downregulation was re-
lated neuropathologically to HIVE, but was not related to
neuropsychological outcome independently. Emulating en-
dogenous synaptic plasticity pharmacodynamically could
enhance synaptic accommodation and improve neuropsy-
chological and neuropathological outcomes in HIV/AIDS.
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Introduction
HIV-1-associated neurocognitive disorders (HAND) remain
highly prevalent in the era of highly active antiretroviral
therapy (HAART) (Heaton et al. 2010; McArthur et al.
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2010). Without HAART the pathophysiology of HAND was
significantly linked with high replication rates of HIV-1 in
the central nervous system (CNS) and a CNS inflammatory
reaction known as HIV encephalitis (HIVE) (Budka et al.
1991). In the era of HAART about 50% of subjects have
neurocognitive impairment to some extent (Heaton et al.
2010) but less than 10% have a neuropathological diagnosis
of HIVE (Masliah et al. 2000; Everall et al. 2009). Early in
the pandemic it was recognized that HIVE was not present
in many subjects with neurocognitive impairment (Glass et
al. 1995; Wiley and Achim 1994), and the divergence may
have widened in the HAART era (Everall et al. 2009;
Gelman 2007). An important role for altered synaptic trans-
mission in HIVE has been widely suggested in the literature.
Synaptodendritic simplification is a neurodegenerative type
of change that occurs in HAND with HIVE (Masliah et al.
1997), and forms a potential therapeutic concept for trans-
lational neuroscience (Gelbard et al. 2010). Transcriptional
regulation of genes that code for presynaptic proteins and
postsynaptic neurotransmitter receptors and ion channels are
perturbed in the dorsolateral prefrontal cortex (DLPFC) of
people with HIVE (Masliah et al. 2004; Gelman et al. 2004).
Isolated synapses from DLPFC in HIVE contain proteomic
changes and altered protein management (Gelman and
Nguyen 2010; Nguyen et al. 2010). Many clinical and
experimental observations suggest that specific neurotrans-
mitter systems and circuits are disturbed. Examples include
striatal dopaminergic circuits (Hriso et al. 1991; Berger and
Arendt 2000; Nath et al. 2000; Nath et al. 2002; Wang et al.
2004a, b; Gelman et al. 2006), basal forebrain cholinergic
circuits (Sarter and Podell 2000; Koutsilieri et al. 2000,
2001a), peptidergic systems including tachykinins, somato-
statin and glutamate (Koutsilieri et al. 2001b; Ho and
Douglas 2004; Da Cunha et al. 1995; Ernst et al. 2010;
Ferrarese et al. 2001; Meisner et al. 2008; Kovacs and De
Wied 1994; Koutsilieri et al. 2001b), and serotonergic
systems (Schroecksnadel et al. 2007; Murray 2003). Collec-
tively, anomalies in synaptic transmission imply that neuro-
nal excitability and circuit functions may be abnormal in
HAND. In turn, neuroprotective strategies that focus on
neuronal excitation and synaptic plasticity could stabilize
neural circuitry and prevent HAND (Gelman et al. 2004; Di
Filippo et al. 2008; Gelbard et al. 2010). Prefrontal dopami-
nergic circuits in HIV/AIDS are especially important because
they undergo disease-associated changes in synaptic tone that
produce abnormal neurocognitive phenotypes (Goldman-
Rakic 1996; Goldman-Rakic 1998; El-Ghundi et al. 2007;
Kroener et al. 2009). Those phenotypes strongly resemble
many of the behavioral anomalies that occur in HAND
(Chang et al. 2008, Heaton et al. 2010; Woods et al. 2009).
In patients with HAND and HIVE the putative driving
force is a combination of brain inflammatory mediators and
HIV-1 proteins that participate in multicellular networks that
damage “bystander” neuronal elements including synapses
(Kaul and Lipton 2006). Many inflammatory mediators
expressed in HIVE can produce functional changes in syn-
aptic transmission experimentally. Interferons (IFNs), cyto-
kines including tumor necrosis factor alpha and interleukins
influence synaptic long term potentiation (D’Arcangelo et
al. 1991; Jankowsky and Patterson 1999; Tancredi et al.
1992; Dafny et al. 1996; Mendoza-Fernandez et al. 2000;
Cunningham et al. 1996; Ross et al. 2003; Hadjilambreva
et al. 2005; Dafny and Yang 2005; Maher et al. 2006;
Khairova et al. 2009), synaptic plasticity (Albensi and
Mattson, 2000; Boulanger et al. 2001; Boulanger 2004;
Stellwagen and Malenka 2006; Jakubs et al. 2008; Kawasaki
et al. 2008; Steinmetz and Turrigian 2010; Yirmiya and Goshen
2011), and synaptogenesis and maintenance (O’Connor and
Coogan 1999; Dafny et al. 1996; Vikman et al. 2001; Kim et
al. 2002; Brask et al. 2004; Mizuno et al. 2008; Boulanger
2009; Victorio et al. 2010). IFNs are especially important in
HIVE because interferon responsive genes (IFRGs) are the
most regulated brain gene expression pathway observed on
arrays (Masliah et al. 2004). HIVE is likely to be a prototypal
clinical example of neuroimmune-associated synaptic dys-
function, but those interrelationships have not been well-
characterized in HIV-1-infected brain specimens. To address
this we performed neurochemical studies in 513 human brain
specimens spanning over two decades of the HIV/AIDS pan-
demic. Dorsolateral prefrontal cortex (DLPFC) was highlight-
ed because the functional output of DLPFC is abnormal in
HAND (Heaton et al. 2010; Woods et al. 2009). Two abnor-
mal neurotransmitter systems were identified and character-
ized. Associations are addressed concerning frontal lobe
dysfunction, neuroimmune changes, neurovirological status,
neuropathology and key comorbidities.
Methods
Brain specimens Preproenkephalin mRNA (PENK) and
type 2 dopamine receptor long splice isoform (DRD2L)
mRNA concentrations were assayed in a total of 513 frozen
human brain samples. 446 were HIV infected patients and
67 were age- gender- and ethnicity-comparable HIV sero-
negative decedents who died during a comparable time span
(Table 1) (Nguyen et al. 2010). 312 out of 446 HIV-infected
subjects died in the HAART era (1998 to 2011) and were
obtained from the National NeuroAIDS Tissue Consortium
(NNTC) (Morgello et al. 2001). Written consent was
obtained for subjects at four collection sites in the USA.
The following offices maintained institutional review boards
(IRBs) that provided oversight for the protection of human
subjects: 1) The University of Texas Medical Branch Office
of Research Subject Protections; 2) Mount Sinai Medical
Center Program for the Protection of Human Subjects; 3)
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University of California, San Diego Human Research Pro-
tections Program; 4) University of California, Los Angeles
Office of the Human Research Protection Program. These
IRBs reviewed the protocol at regular intervals and gave
written approvals continuously over 12 consecutive years to
the present. Most HAART-era subjects underwent neuro-
cognitive evaluations and substance use surveys using the
NNTC protocol, as indicated in tables and figures. 134
of the decedents with HIV/AIDS were archived in the
20th Century and prior to HAART (between 1988 and
1996) in Galveston, Texas, USA. Texan subjects who
underwent a complete autopsy before the NNTC did
not undergo a structured neurocognitive evaluation; their
pathological characteristics have been reported (Gelman
et al. 1996).
Neurocognitive testing, substance use survey, neuropatho-
logy Two hundred seventy two out of 312 HAART-era
subjects were clinically assessed for neurocognitive impair-
ment by a neuropsychologist. 218 out of 272 underwent a
structured battery of neurocognitive tests employed by the
NNTC at 6 month intervals until autopsy (Morgello et al.
2001). All results were obtained within 6 months prior to
death. A composite normalized impairment T score was
obtained, and seven normalized component neurocognitive
domain T scores were evaluated. The consistency of neuro-
cognitive testing across the four NNTC specimen collection
sites was maintained with a structured quality assurance pro-
gram. Evaluations were scored according to age-adjusted
norms and clinical diagnoses were assigned according to
modified American Academy of Neurology criteria (Woods
et al. 2004). One of four neurocognitive diagnoses was con-
sidered: a) No syndromic neurocognitive impairment; b) mild
cognitive and motor disorder (MCMD); c) HIV-1-associated
dementia (HAD); d) impairment possibly caused by medical
factors other than HIV/AIDS (NPI-O). A diagnosis of syn-
dromic impairment included the diagnoses of MCMD and
HAD, but not NPI-O. The nosological diagnosis of HAND
(Antinori et al. 2007) was not used in the present study
because: 1) very few subjects in the NNTC autopsy cohort
have a diagnosis of “no HAND,” and 2) this study and the
NNTC began before the establishment of the nosological
diagnosis of HAND.
The Psychiatric Research Interview for Substance and
Mental Disorders (PRISM) was used to obtain self-
reported lifetime histories of substance abuse and depen-
dence. A quality assurance program was followed to main-
tain consistency across the four NNTC test sites (Morgello
et al. 2006). Neuropathological diagnoses were rendered by
NNTC site neuropathologists (B. Gelman, Texas; S. Morgello,
New York; E. Masliah, San Diego; D. Commons, Los
Angeles). Consistency across all four NNTC collection sites
was maintained by using a uniform sampling strategy and
following a structured program of quality assurance that
Table 1 HIV positive decedents with and without HIV encephalitis and seronegative controls
Characteristic HIV Infectiona p HIV encephalitisb p
HIV- HIV+ HIV- vs HIV+ HIVE- HIVE+ HIVE- vs HIVE+
Number of subjects 67 446 N/A 354 92 N/A
Agec 46.9±13.6 42.6±9.6 0.001 43±10 41.2±7.8 0.106
Gender (M/F)d,e 53/14 384/62 0.133 299/55 85/7 0.050
Race (W/B/A/O)e,f 41/20/0/6 271/146/6/23 0.468 218/113/6/17 53/33/0/0 0.091
Hispanic or Latino (yes/no)e 16/51 88/358 0.431 65/289 23/69 0.154
Postmortem freezing intervalc 15±11.5 14.5±14.7 0.787 14.1±13.4 16.0±19 0.268
Log10 Plasma HIV RNA
(copies/ml)c (n0263)




N/A 2.8±1.5 N/A 2.6±1.3 4.2±1.7 <0.001
Blood CD4+ lymphocyte
count (cells/mm3)c (n0272)
N/A 106±162 N/A 119±175 52.3±64.5 0.007
a HIV-, Human Immunodeficiency Virus seronegative; HIV+, seropositive
b HIVE, HIV encephalitis
cMean ± standard deviation, Student’s t test
dM/F, Male/female
e Chi square
f B/W/A/O, Black/White/Asian/Other or not known
gN/A, not applicable
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consisted of frequent face-to-face reviews using a multi-
head microscope. Criteria used for the nosological diagnosis
of HIVE were according to Budka et al. (1991).
Brain dissection and RNA isolation DLPFC was empha-
sized because gene arrays and proteomic studies indicate
that synaptic disturbances occur in that sector (Masliah et al.
2004; Gelman and Nguyen 2010). Frozen samples of
DLPFC were dissected from Brodmann areas 9 or 10. The
Qiagen RNeasy Lipid Tissue Mini Kit (Cat. No. 74804,
Valencia, CA, USA) was used to prepare RNA. About
100 mg of brain tissue was dissected on dry ice and placed
in 1 ml of QIAzol and 0.5 g of 0.5 mm Zirconia/Silica beads
(Cat. 11079105z, BioSpec Products, Bartlesville, OK,
USA). Samples were homogenized using three 20 s pulses
in a mini-bead beater. At room temperature 200 μl chloro-
form was added with shaking for 15 s, and after standing
3 min was centrifuge at 12,000 x g for 15 min at 4°C. One
volume of 70% ethanol was added to the aqueous phase
with mixing. Up to 700 μl of the extract was added to
RNeasy mini spin columns in a volume of 2.0 ml. After
centrifuging for 15 s at 8000 x g at room temperature the
spin was repeated with the remainder of the extract. Col-
umns were washed with 350 μl Buffer RW1 and treated
with RNase-free DNase I (Cat. 79254, Qiagen, Valencia,
CA, USA) at room temperature for 15 min. 350 μl Buffer
RW1 was added to the columns and centrifuged for 15 s at
8000 x g. Columns were washed with 500 μl Buffer RPE
twice, and re-centrifuged at maximum speed for 2 min to
remove salts. RNA was eluted twice with 50 μl RNase-free
water.
Assay of PENK, DRD2L, IRF1, GAPDH and HIV-1 gag/pol,
mRNA expression Bio-Rad iScript cDNA Synthesis Kit
(Cat. No. 170-8891, Hercules, CA, USA) was used to syn-
thesize cDNA. 1 μg of brain RNA, 4 μl of 5x iScript
reaction mix, 1 μl of iScript reverse transcriptase was ad-
justed to 20 μl with nuclease-free water. The mixture was
incubated for 5 min at 25°C, 30 min at 42°C, 5 min at 85°C,
then held at 4°C. HIV cDNA was prepared using HIV anti-
sense primer 84R in a final concentration of 1 μmol/L
(Palmer et al. 2003). PENK primer sequences used were:
AGAAGGCGAAAGTTACTCCAA and CACCATCAA
CAGTTTCCCAC; PENK probe sequence: Fam-ACTAG
TGGCCCCAGGCCCCA-TAMRA. Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) was used as normaliz-
ing gene. GAPDH primer sequences: GAAGGTGAAGGT
CGGAGTC and GAAGATGGTGATGGGATTTC;
GAPDH probe sequence: Fam-CAAGCTTCCCGTTCTCA
GCC-TAMRA. All reagents were from Sigma Genosys
(The Woodlands, TX, USA). For each reaction, 12.5 μl of
2x JumpStart Taq ReadyMix for Quantitative real time PCR
(Sigma, St. Louis, MO, USA) (Cat. No. D7440) was
combined with 1 μl of cDNA, 3.5 μl of 25 mmol/l MgCl2,
0.8 μl of 10 μmol/l primer mix and 0.5 μl of 10 μmol/
l probe adjusted to a volume to 25 μl with water. PCR
conditions were 2 min at 95°C, 40 cycles of 15 s at 95°C
and 60 s at 60°C. For assay of the long splice isoform of the
type 2 dopamine receptor, 1 μl of 20x DRD2L primers and
probe mix (Cat. Hs01024460_m1, Applied Biosystems,
Foster City, CA, USA) was combined with 1 μl of cDNA,
10 μl of 2x JumpStart Taq ReadyMix, 2.5 μl of 25 mmol/
l MgCl2 adjusted to 20 μl with water. GAPDH mRNA was
used as normalizing transcript in reactions analogous to the
above using 1 μl of 10 μmol/L GAPDH primer mix and
0.5 μl of 10 μmol/L GAPDH probe. For assay of interferon
regulatory factor 1 (IRF1), IRF1 mix (Hs00971959_m1),
GAPDH mix (Hs99999905_m1) and TaqMan Universal
PCR Master Mix (Part No. 4304437) were used (Applied
Biosystems, Foster City, CA, USA) with PCR conditions as
above. Real time PCR was run using an Eppendorf RealPlex
(Hamburg, Germany) and gene relative expression was cal-
culated using the ΔΔCt method. Each sample was run in
duplicate. Two standard calibrator mRNA isolates from
brain were run on every plate when calibration between runs
was necessary. Brain HIV RNAwas quantified using cDNA
derived from the brain total RNA isolated as above. The
HIV gag/pol primer and probe sequences were from Palmer
et al. (2003). The reaction contained 4 μl of cDNA, 12.5 μl
of Sigma JumpStart Taq ReadyMix, 3.5 μl of 25 mmol/L
MgCl2, 0.8 μl of 10 μmol/L HIV primer mix and 0.5 μl of
10 μmol/L HIV probe adjusted to 25 μl. PCR conditions
were as above. RNA copy per microgram of total RNAwas
calculated using a standard curve using a previously quan-
tified HIV-positive RNA sample as the primary standard.
HIV RNA copy per gram of brain tissue was calculated
using RNA extraction yield (mg/g) divided by the starting
wet weight of the brain tissue sample.
Statistics HIV-infected subjects with and without HIV en-
cephalitis (HIVE) were compared to HIV negatives and to
each other using one-way analysis of variance with post hoc
comparisons using Tukey’s test. The groups of HIV infected
subjects with and without syndromic neurocognitive impair-
ment were compared to each other and the HIV negatives as
above. For correlation analysis in which there was little
deviation from linearity such as for normalized T scores,
Pearson’s product moment correlation was used. Spear-
man’s rank test was used when deviation from linearity
was prominent, such as for IRF1. The significance of the
correlations was corrected for the false discovery rate
(Benjamini and Yekutieli, 2001) using alpha00.05. Using
the HIV-infected subjects who underwent the substance
abuse survey, multiple logistic regression models with step-
wise elimination was used to determine whether nine cate-
gories of abuse in the PRISM survey were related to the two
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synaptic mRNAs. These models included any kind of sub-
stance abuse as one potential independent variable. The
pooled students t test was used when two mutually exclusive
groups were compared to each other (such as with major
depression versus without, or with Hepatitis C infection
versus without). When two correlations were compared to
each other (such as the correlations between IRF1 and
synaptic markers) the bootstrap approach was used (Efron
1979). The general significance level was p<0.05 using a
two tailed probability.
Results
PENKandDRD2L expression PENK had significant between-
group effects comparing controls to HIV positives with and
without HIVE (F03.45, p<0.0335) (Fig. 1a). The subjects
with HIVE had an average decrease of 37% (p<0.0252,
Tukey’s test); the subjects without HIVE did not have a
significant decrease in PENK (p<0.2049). The difference
was evident both before and during the HAART era
(Fig. 1b,c).
Gene array data have suggested that DLPFC DRD2L
mRNAwas regulated in HAND (Gelman et al. 2004) and this
survey confirmed it (Fig. 1d). There was a significant
between-group effect using one-way ANOVA DRD2L (F0
7.78, p<0.0005). DRD2L was lower by an average of 26% in
the HIV infected subjects without HIVE (p<0.0021) but was
not lower in the subjects with HIVE (p<0.6117). The differ-
ence was evident both before and during the HAART era
(Fig. 1e,f).
Results with or without HIVE suggested that PENK and
DRD2L mRNAwere not downregulated in the same subjects.
Indeed, the two synaptic mRNAs appeared to run in opposite
directions in HIV-infected subjects (Fig. 2a). The linear cor-
relation coefficient between the two mRNAs after log trans-
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response factor 1 (IRF1)
mRNAs in frontal neocortex in
67 seronegative patients and
446 patients with HIV/AIDS
(Panels a, d, g). “Rel. expr.” on
the ordinate denotes mRNA
expression relative to GAPDH
mRNA. The 446 subjects with
HIV/AIDS were subdivided
into groups without and with
HIV encephalitis (HIVE)
(n0354 and 92 respectively).
Panels b, c, e, f, h, i show the
composite data split into
subjects who died before
(n0111 and 23) and during
(n0243 and 69) the era of
highly active antiretroviral
therapy (HAART). The
between group analysis using
one-way analysis of variance
was significant for PENK
(F03.45, p<0.0335), DRD2L
(F07.78, p<0.0005), and IRF1
(F07.03, p<0.0010). PENK
was lower in the subjects with
HIVE (p<0.0252); DRD2L was
lower in the subjects without
HIVE (p<0.0021); IRF1 was
higher with and without
HIVE (p<0.0007 and 0.0060
respectively). The patterns were
present prior to and during
the era of HAART. Mean ±
standard deviation
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Relationship to interferon response The above indicated
that HIVE was related to the dysregulation of PENK and
DRD2L. Brain specimens with HIVE usually have higher
host neuroimmune responses such as interferon response
gene (IFRG) expression (Masliah et al. 2004) and increased
brain HIV RNA concentration (Achim et al. 1994). To
determine whether IFRG expression was related to the syn-
aptic mRNAs, a prototypal IFRG mRNA was assayed. In-
terferon regulatory factor mRNA (IRF1) (Gobin et al. 1999)
was increased significantly (F07.03, p00.0010) by 2.2 fold
in subjects without HIVE (p<0.0060), and by 2.7 fold in the
subjects with HIVE (p<0.0007) (Fig. 1g). Correlation anal-
ysis showed that log IRF1 was significantly and negatively
correlated with PENK (r0−0.241, p<2.70E-07, Pearson’s
test) (Fig. 2b). Log IRF1 was significantly and positively
correlated with log DRD2L (r0+0.214, p<5.30E-06)
(Fig. 2c). Using the bootstrap approach the two correlations
were significantly different from each other (p<10E-06).
Relationship to brain HIV RNA concentration In contrast to
the significant correlations with IRF1, correlation coeffi-
cients between the synaptic mRNAs versus log brain HIV
RNA concentration were not significant. A weak threshold
concentration of 10E+05 copies of HIV RNA per gram of
wet brain tissue was suggested that was significant for
increased DRD2L (0.0131±0.0081 below versus 0.0154±
0.0105 above, p<0.019, student’s t test), but not for de-
creased PENK (p<0.099).
Relationship to neurocognitive impairment HIV infected
subjects with and without neurocognitive impairment were
compared to each other, and to seronegative controls
(Fig. 3). One-way ANOVA showed a significant between
group effect for DRD2L (F05.13, p00.0065) but not PENK
(F02.36, p00.0962). The post hoc analysis showed that
subjects who did not have impairment had a 36% decrease
inDRD2L (p<0.0043); the subjects who did have impairment
had a decrease of 17% in DRD2L that was not statistically
significant (p<0.1619). We performed linear regression anal-
ysis using the composite neurocognitive impairment T score
(a normalized measure of composite performance) and found
a significant negative correlation with DRD2L (Table 2). The
minus sign of the correlation coefficient indicated that lower
DRD2L expression was linked with stronger performance (a
higher T score) and a more favorable neurocognitive outcome
overall.
The composite diagnosis of neurocognitive impairment
takes into account several component functional “domains”
(Woods et al. 2004). To determine whether DLPFC DRD2L
expression was correlated selectively with specific types of
tasks, multiple correlations using the component domain T
scores were computed (Table 2). Negative correlation coef-
ficients were obtained for performance on tasks that re-
quired verbal fluency, working memory formation and
rapid information processing. These r-values were signifi-
cant after correction for the false discovery rate due to
multiple comparisons. These tasks are driven characteristi-
cally by the frontal lobes, and are modulated by DLPFC
dopaminergic tone (Parks et al. 1988; Sawaguchi et al. 1990;
Goldman-Rakic 1996; Goldman-Rakic 1998; Gulledge and
Jaffe 1998; Schlosser et al. 1998; Baddeley 2003; Tierney et
al. 2008; Nagano-Saito et al. 2008; Kroener et al. 2009). For
tasks driven primarily by temporal lobe circuits such as
learning and memory formation (Squire and Zola-Morgan
1991), the correlation coefficients were not as strong and were
not significant after adjustment for the false discovery rate
(Table 2).
Relationships to substance abuse history, depression, Hepatitis
C virus and age Substance use survey results were available
in 194 of the HIV infected subjects. 76 had a least one
substance of abuse and 118 had no abuse. The number of
subjects in each category of abuse was: alcohol050; can-
nabinoids028; cocaine034; hallucinogens08; opiates011;
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r = 0.214
p = 5.3E-06
Fig. 2 Changes in preproenkephalin (PENK) and dopamine receptor
(DRD2L) mRNA expression in frontal neocortex in 446 HIV-infected
subjects. PENK and DRD2L tended to run opposite to each other; the
correlation coefficient was significant with a negative slope (a). When
compared to the inflammatory marker IRF1 mRNA, PENK and
DRD2L both were significantly correlated. PENK was correlated with
a negative slope (b); DRD2L was correlated with a positive slope (c).
Using the bootstrap approach, the correlations in b and c are signifi-
cantly different from each other (p<0.001)
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regression models were used to address the fact that multiple
substances may be abused. Using DLPFC PENK as the
response, the models showed that all p-values were greater
than 0.2, and the overall p-value was not significant (F0
1.293, p00.2505) using the Bayesian Information Criterion
(BIC). A potentially important p-value for 11 subjects with
opiate abuse of 0.0141 was obtained using Akeike’s Infor-
mation Criterion (AIC), implying a possible relationship
between opiate abuse and lower PENK expression. Multiple
regression models using DRD2L as the response showed
that all of the p-values for the individual categories of abuse
were above 0.15, and the overall p-value was not significant
(F01.03, p00.418).
The high prevalence of major depressive disorders (MDD)
in HIV-infected cohorts (Berger-Greenstein et al. 2007) could































































response factor 1 (IRF1)
mRNAs in frontal neocortex
(a, b and c respectively). “Rel.
expr.” on the ordinate denotes
mRNA expression relative to
GAPDH mRNA. On the
abscissa 67 HIV negative
subjects (HIV-) are compared
to 146 HIV positive subjects
(HIV+) with neurocognitive
impairment (NPI), and 57
HIV+ subjects without NPI.
The between group differences
using one-way ANOVA
were significant for DRD2L
(F05.13, p<0.0065) and IRF1
(F06.38, p<0.0020). DRD2L
was significantly lower in
subjects without NPI
(p<0.0043, Tukey’s test).
Mean ± standard deviation
Table 2 Correlation between normalized neurocognitive T scores and prefrontal synaptic mRNAs
Neurocognitive test domain n a DRD2L mRNA b PENK mRNA
r c p d r p
Verbal Fluency 215 −0.2450 0.0003* 0.0444 0.5168
Attention and working memory 211 −0.2180 0.0014* 0.0116 0.8661
Speed of Information processing 216 −0.1983 0.0034* 0.0232 0.7339
Motor 202 −0.1675 0.0171 0.0502 0.4778
Learning 218 −0.1653 0.0145 −0.0445 0.5127
Abstract Executive 208 −0.1461 0.0352 0.0363 0.6019
Memory 217 −0.1004 0.1404 −0.0916 0.1787
Composite T score, all tests 196 −0.2394 0.0007* 0.0051 0.9434
a n, number of subjects with available T score
bDRD2L mRNA, dopamine receptor type 2 long splice isoform messenger RNA; PENK mRNA, preproenkephalin
c r, Pearson’s correlation
d p, Two-tailed probability
*Bold denotes significant statistically after controlling for the false discovery rate. The composite score does not require adjustment; its p-value is
significant with or without correction
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Hurd 2001; Tremblay et al. 2005; Kennedy et al. 2006) and/or
the neurocognitive output of the DLPFC (Ottowitz et al. 2002;
van der Werf-Eldering et al. 2010). In 91 subjects with MDD
versus 100 without it, neither PENK (0.0105±0.0087 vs
0.0123±0.0120, p<0.264) nor DRD2L (0.0130±0.0095 vs
0.0132±0.0079, p<0.892) was significantly different.
Hepatitis C virus (HCV) infection can influence HAND,
especially in the presence of MDD (Clifford et al. 2005).
The two synaptic mRNAs were not expressed differently
comparing subjects with (n079) and without (n0116) docu-
mented HCV infection (PENK: 0.0107±0.0102 vs 0.0117±
0.0104, p<0.504; DRD2L: 0.0139±0.0079 vs 0.0147±
0.114, p<0.586).
Advanced age has been reported to be associated with
lower DRD2 binding availability to the extent of about 0.6%
per year (Antonini et al. 1993; Volkow et al. 2000), and also
with higher brain inflammation (Dickson et al. 1992). The
HIV infected subjects in the autopsy cohort were slightly
younger than controls (4 years on average, see Table 1), and
raised the possibility that a younger average age might have
influenced neurochemical outcomes. The t-test of the coef-
ficient in a regression model testing the effects of HIV and
age together showed that IRF1 was higher (p<0.001),
PENK was lower (p00.022) and DRD2L was lower (p0
0.0597). Thus, age did not drive the changes observed in
HIV infected subjects substantially, although a small influ-
ence of age on these outcomes remains difficult to exclude
completely.
Discussion
The study confirms that mRNA changes associated with
altered synaptic transmission in frontal neocortex are prev-
alent in people with HIV/AIDS. At least 40% of the HIV
infected population had downregulation of at least one of
the two synaptic mRNAs. The abnormal synaptic mRNA
pertaining to dopaminergic neural transmission (DRD2L)
was correlated significantly with neurocognitive impair-
ment, while the abnormal enkephalin-related mRNA
(PENK) was not correlated with impairment independently.
The fact that the two synaptic mRNAs were regulated in the
opposite direction from each other implies that the changes
do not reflect a generalized loss of synapses in the setting of
neurodegeneration. Instead, the functional implications of
the results pertain to synaptic plasticity and the circuit level
output of the frontal lobes. Neurotransmitter “tone” is dy-
namically regulated in many ways. Modulating the concen-
tration of the neurotransmitter presynaptically (illustrated
with PENK regulation) or changing the number of receptors
postsynaptically (illustrated with DRD2L regulation) repre-
sent established aspects of synaptic plasticity (Malenka and
Nicoll 1993; Elgersma and Silva 1999; Citri and Malenka
2008). Changes in synaptic tone at the cellular level produce
shifts in neuronal excitation; dopaminergic and opioidergic
tone both modify neuronal excitability at the cellular level
(Xie and Lewis 1995; Otani et al. 2003). In turn, synaptic



















Fig. 4 Preproenkephalin mRNA concentration (PENK) in frontal neo-
cortex of HIV-infected subjects is plotted versus substance abuse
categories. “Rel. expr.” on the ordinate denotes mRNA expression
relative to GAPDH mRNA. Drug abuse was diagnosed using the
Psychiatric Research Interview for Substance and Mental Disorders
(PRISM). Drug abuse categories are given on the abscissa. “Other”
denotes several substances such as inhalants. See “Results” for the
number of subjects in each category. PENK was not significantly
different in any substance abuse category using multiple regression
models. Compared to subjects without any abuse (left bar), eleven
subjects with opiate abuse had a trend towards having significantly
less PENK using stepwise regression models that was of marginal
significance (see “Results”). DRD2L mRNA also showed no signifi-
cant group effect (not illustrated). Mean ± standard deviation
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neural networks (Citri and Malenka 2008; Boulanger 2004).
Clinically, circuit-level changes in DLPFC output modify
neurocognitive test performance on tasks pertaining to ver-
bal fluency, working memory formation, and speed of pro-
cessing (Sawaguchi et al. 1990; Gulledge and Jaffe 1998;
Schlosser et al. 1998; Goldman-Rakic 1996; Tierney et al.
2008). All of those kinds of tasks were correlated signifi-
cantly with DLPFC DRD2L expression in HIV/AIDS
(Table 2). Dopamine receptive neurons in the DLPFC that
express DRD2L play a critical role in controlling the output
of frontal lobe circuits (Goldman-Rakic 1998; Wang et al.
2004a, b; Nagano-Saito et al. 2008; Kroener et al. 2009). In
primates these neurons are concentrated in the excitatory
output neurons in cortical Lamina V. Their excitation state
fundamentally controls DLPFC circuit output (Lidow et al.
1998; Wang et al. 2004a, b; Cohen et al. 2002). Enkephali-
nergic neurons and cognate delta opioid receptors in DLPFC
also are localized in Lamina V and vertically connected
neurons in Laminae II and III (McGinty et al. 1984;
Mansour et al. 1993). The cortical enkephalinergic system
also influences frontal lobe output (Verdejo et al. 2005).
Together these abnormal synaptic systems can exert sub-
stantial control on the functional output of the frontal lobe
circuitry, and thus, might drive frontal lobe dysfunction in
HAND and HIVE (Woods et al. 2004).
The type 2 dopamine receptor (DRD2L) is a pivotal point
of neural circuits that originate in the midbrain, such as the
mesofrontal circuit in DLPFC (Goldman-Rakic 1998) and
the classical “direct” striatopallidal circuit (Gerfen et al.
1990). DRD2L expression often is a transcriptionally active
marker gene in dopamine receptive neurons that responds
dynamically to changes in synaptic dopaminergic tone
(Gerfen et al. 1990; Angulo et al. 1991; Volkow et al.
1999; Trantham-Davidson et al. 2004; Seamans and Yang
2004; Sesack and Carr 2002), and also can modulate PENK
expression (Gerfen et al. 1991; Morris and Hunt 1991;
Przewłocka and Lasoń 1995; Steiner and Gerfen 1999).
Regulating dopaminergic tone in the mesofrontal circuitry
has consequences that are potentially both favorable and
unfavorable. DLPFC output responds to dopaminergic tone
in an “inverted U” type of dose–response curve, in which
excessive deviation in either direction modifies synaptic
tone and can produce DLPFC dysfunction (Nagano-Saito
et al. 2008; Cools and D’Esposito 2011; Monte-Silva et al.
2009). One stimulus that shifts the inverted U response
curve and drives DLPFC DRD2L expression lower is in-
creased presynaptic dopaminergic tone (Ito et al. 2011;
Sesack and Carr 2002; Volkow et al. 1999). In HIV/AIDS
the functional output of the DLPFC was most favorable
when DRD2L expression was downregulated, which implies
a compensatory shift to a more favorable point on the
inverted U response curve. Conversely, DLPFC output was
less favorable when DRD2L showed no net downregulation
(Fig. 3), which implies a less optimal point on the inverted U
response curve. Thus, decreased DRD2L expression probably
reflects a compensatory lowering of dopaminergic set point to
synaptically accommodate, and stabilize DLPFC output
(Floresco and Magyar 2006). We suggest that this is the most
likely reason why failing to drive dopaminergic tone down-
ward was associated with less beneficial outcomes. The fact
that an unfavorable neurocognitive outcome was associated
with “normal” DRD2L expression is seemingly paradoxical.
But those results are in substantial accord with clinical obser-
vations, including some work with HIV-infected subjects.
Using functional magnetic resonance spectroscopy (MRS) it
was shown that many subjects with task-driven functional
abnormalities of frontostriatal circuitry, and/or glial activation
(Melrose et al. 2008; Ernst et al. 2002; Meyerhoff et al. 1999),
do not have HIV-associated neurocognitive impairment. Con-
versely, many subjects without those synaptic accommoda-
tions (i.e. appear “normal” in the brain images) do have
impairment. These types of clinical observation in HIV/AIDS,
in conjunction with the vast experimental literature on pre-
frontal dopaminergic systems, suggest the scenarios that are
illustrated in Fig. 5: 1) DLPFC dopaminergic circuit accom-
modation does occur in some subjects with HIV/AIDS. 2)
When it occurs it appears to be beneficial to frontal lobe output
as depicted in scenario C. 3) When it fails to occur it is
potentially unfavorable as depicted in scenario B. 4) Brain
inflammation and/or HIVE (represented by the interferon
response gene IRF1) seems to drive DRD2L expression
upward and has an unfavorable influence on DLPFC
dopaminergic tone, and possibly, enkephalinergic tone
as in Scenario D.
Brain imaging in subjects with HAND has suggested that
neostriatal ligand binding availability is low for postsynaptic
DRD2 and the presynaptic dopamine reuptake transporter
(DAT). Those results are generally taken to suggest that
striatal dopaminergic tone is abnormal, although the techni-
cal approaches used were not sufficiently sensitive to detect
a change in the DLPFC (Chang et al. 2008). Indeed, assay of
synaptic mRNAs was the chosen approach at autopsy pri-
marily because detection of neocortical protein elements
was out-of-range. Beyond the problem of detection, each
dopaminergic circuit has interdependent regulatory proper-
ties that often run opposite to each other (Wilkinson 1997;
Kellendonk et al. 2006). Despite the technical differences,
autopsy results agree that dopaminergic transmission is re-
lated to HIV-associated neurocognitive dysfunction. The
decreased transcription regulation of DRD2L at autopsy is
consistent with a loss of raclopride binding availability of
DRD2 in the neostriatum (Chang et al. 2008). As well, the
suggestion that increased presynaptic tone could drive the
changes (as illustrated in Fig. 5) is consistent with having
decreased dopamine binding availability of DAT. In the
latter scenario, a higher concentration of endogenously
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synthesized dopamine in the synaptic cleft could compete
with exogenous radiotracer dopamine and reduce its binding
availability, which is what was observed in neostriatum
(Chang et al. 2008).
The mechanism that produces altered dopaminergic
transmission in HIV/AIDS is of great interest and needs to
be elucidated. Experimental evidence shows that HIV-1 can
interact directly with dopaminergic synapses. Specifically,
the concentration of HIV-1 transactivator of transcription
protein (Tat) which is known to be toxic, influences the
physiochemical interplay between dopamine and neostriatal
DAT, and could disturb dopamine binding availability to
DAT (Zhu et al. 2011). Pertinent to that suggestion, the
autopsy survey showed that the concentration of HIV gag/
pol RNA in the brain was not correlated significantly with
DRD2L expression. A history of taking HAART to suppress
HIV replication also showed no apparent relationship at
autopsy. Those observations imply that the concentration
of HIV-1 proteins such as Tat do not directly drive DRD2L
regulation. The same could apply to DAT binding availabil-
ity, although the issue was not addressed specifically at
autopsy because presynaptic DAT and its mRNA could not
be detected consistently in the DLPFC.
One implication for future work is that inflammatory type
mediators such as the IFNs might be directly involved with
dopaminergic transmission in HIV/AIDS. Autopsy data im-
plied that inflammation was associated with higher DRD2L
and lower PENK (Fig. 2). This was illustrated using a
prototypal IFN-γ-responsive gene (IFRG); other inflamma-
tory mediators produced equivalent results (not illustrated).
IFNs and IFRGs are neuroimmune mediators of prime in-
terest because they are strongly expressed in virus infected
brain tissue including HIVE (Masliah et al. 2004; Sas et al.
2009). The connection between the IFRG expression and
synapse biology in HIV/AIDS agrees fundamentally with a
broad base of experimental data (see the extensive list of
pertinent citations in the introduction). IFN and other neuro-
immune mediators modify synaptic functions directly by
driving IFN receptors on neurons (Neumann et al. 1997;
Delhaye et al., 2006; Mizuno et al. 2008; Sas et al. 2009;
Dafny 1998), and indirectly by increasing the synthesis of
IFRGs. IFNs act upon two types of receptors that drive the
expression of hundreds of IFRGs (Boehm et al. 1997;
Theofilopoulos et al. 2005). Examples of indirect action of
IRF-1 include the induction of class I major histocompati-
bility antigens, and nitric oxide synthesis (Martin et al.
1994; Hobart et al. 1997), which in turn modify synaptic
long term potentiation (Garthwaite and Boulton 1995;
Goddard et al. 2007). Experimental data show that increased
IFN-γ also lowers PENK mRNA expression (Low et al.
1992; Negro et al. 1992; Ovadia et al. 1996), as observed
in the subjects with HIVE (Fig. 1). Experimentally, the
proposed linkage between heightened immune responses






























Fig. 5 Prefrontal dopamine receptive neurons in HIV infected subjects
often have abnormal mRNA expression of genes that are critical for
synaptic transmission. The proposed functional implications for a
dopaminergic synapse of a Lamina V pyramidal neuron are illustrated
in four scenarios designated a, b, c and d. Scenario A depicts baseline
dopaminergic tone in a normal person. Scenario B depicts no change in
postsynaptic DRD2L; subjects fitting that picture were more likely to
have neurocognitive impairment and high excitatory frontal lobe out-
put. Scenario C depicts a decrease in postsynaptic DRD2L due to
accommodation; subjects fitting that picture were less likely to have
neurocognitive impairment and lower excitatory output. Scenario D
depicts HIV encephalitis which produces an increase in inflammatory
mediators; subjects fitting that picture probably had bidirectional
changes in DRD2L, including increased expression when inflammation
and HIVE were present. Inflammation and HIVE also were associated
with decreased PENK expression, which ran opposite to DRD2L reg-
ulation. The nature of the suggested connection between dopaminergic
and enkephalinergic transmission remains to be elucidated. Key: The
presynaptic bouton is on top and postsynaptic bouton is below. For the
purpose of illustration, the postulated driver of postsynaptic DRD2L
expression is increased presynaptic dopaminergic tone (the cause is not
clear). A larger size of the DRD2L symbol denotes higher receptor
mRNA expression. Bolder arrows denote stronger receptor transduc-
tion. Bolder lightning bolts denote stronger depolarization or high
firing rates. A high density of presynaptic vesicles symbolizes higher
presynaptic tone
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feedback loops. For example, opioid neuropeptides includ-
ing PENK drive neuroimmune cellular responses forward,
including increased macrophage and lymphocyte infectivity
with HIV-1 (Nath et al. 2002; Wetzel et al. 2000). A feed-
back loop is suggested in which heightened neuroimmunity
leads to PENK downregulation and weakens HIV-1 replica-
tion. Dopamine and serotonin also modify macrophage
HIV-1 replication via their cognate receptors, and could
engage in similar feedback loops (Maneglier et al. 2008;
Gaskill et al. 2009). The suggested scenarios need to be
confirmed in model systems focusing on receptor proteins
and their endogenous agonists.
Substance abuse is prevalent in HIV-infected populations.
It is associated with altered neural transmission (Wolf 2002;
De Vries and Shippenberg 2002), including lower striatal
DRD2 mRNA expression, and especially with cocaine and
methamphetamine use (Volkow et al. 1999; Goldstein and
Volkow 2002; Chang et al. 2008). Substance abuse also can
change neurocognitive function pertaining to DLPFC output
(Nath et al. 2002). The linkage of substance abuse with lower
DRD2 expression implies that it also could be associated with
synaptic “accommodation” as illustrated in Fig. 5, which in
turn, could prove to be favorable in terms of neuropsycholog-
ical performance. We did not detect associations between sub-
stance use and neurochemical changes at autopsy using a self
report survey, probably because a postmortem survey is affect-
ed by multiple confounding factors during a human lifetime.
Drugs are often abused intermittently, using complex combi-
nations of substances, for varying durations. Acute intoxica-
tion, binging, fatal overdoses and undocumented abstinence
periods all can influence synaptic tone, yet cannot be controlled
for generally in an autopsy survey. Another potentially impor-
tant influence to consider is nicotine dependence, which can
stimulate dopamine release in the striatal reward pathway and
produce loss of radiotracer ligand binding to DRD2. Nicotine
use modified the strength of the association between HIV
infection and striatal DAT binding availability in the study by
Chang et al. (2008). Smoking histories were not available in the
autopsy survey, so the lower DRD2L expression with HIV/
AIDS might have been influenced by nicotine use. The great
complexity introduced by multiple historical variables suggests
that the influence of substance abuse needs to be unraveled
using corollary experimental paradigms of HIV infection.
In addition to acquired factors that occur intermittently
before death, innate factors such as host genetic polymor-
phism might be important. The host genome could produce
enduring effects on synaptic mRNA regulation primarily
because it does not fluctuate with time. DRD2L gene poly-
morphism modifies DRD2L mRNA expression and changes
the functional output of the DLPFC (Duan et al. 2003;
Zhang et al. 2007). As well, enzymatic degradation of
synaptic dopamine by catechol-O-methyltransferase (COMT)
is influenced by host polymorphism of COMTwhich in turn,
can modify dopaminergic output of the DLPFC (Egan et al.
2001). In that scenario a subject would acquire lowDRD2L or
PENK expression (and potential synaptic accommodation)
prior to acquiring HIV/AIDS. If host genes can indeed drive
DRD2L expression, vulnerable subjects with inherently less
favorable genes, and weaker synaptic accommodation, could
be identified a priori and treated aggressively with measures to
stimulate accommodation and promote more favorable neuro-
psychological outcomes. Similarly, less vulnerable subjects
might be identified clinically. Neuropharmacological manipu-
lation of opioidergic and dopaminergic tone represents a logical
way to mimic naturally occurring synaptic accommodation to
improve neurocognitive function (Hille et al. 2001; Cohen and
Servan-Schreiber 1992). The suggested approach acts down-
stream from brain neuroimmune activation, and is an attractive
site of action because neural immunity must be preserved in
order to control brain HIV-1 replication, suppress viral latency
or participate in therapeutic virus eradication paradigms.
Summary Neurochemical measurements in 512 autopsy brain
specimens lend strong credence to the hypothesis that synaptic
modulation occurs often in the DLPFC of subjects with HIV/
AIDS. Dopaminergic and opioidergic neurotransmitter sys-
tems were regulated transcriptionally and exhibited various
linkages to brain neuroimmunity, brain pathology and brain
function. The most important association that was established
is that decreased expression of DRD2L in frontal neocortex
was linked to a more favorable neuropsychological outcome.
Coordinated neuropharmacological manipulation of such neu-
rotransmitter imbalances could modulate the brain circuits that
drive neurocognitive impairment or provide synaptic accom-
modation in HIV/AIDS. Protecting circuit level function phar-
macodynamically is a therapeutic approach that preserves host
neural immunity and is potentially complementary to HAART.
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